At week 48 of the Phase II trial, 65 percent of patients with Crohn's disease receiving Tremfya® achieved clinical remission.
List view / Grid view
Tremfya inhibited radiographic progression and provided durable improvements in symptoms of axial involvement in psoriatic arthritis patients.
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya® (guselkumab) were maintained over two years.
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.